公开(公告)号：EP1706385A1

公开(公告)日：2006-10-04

申请号：EP04806258.2

申请日：2004-12-23

申请人： Astex Therapeutics Limited ,  Cancer Research Technology Limited ,  THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

发明人： BERDINI, Valerio ,  SAXTY, Gordon ,  VERDONK, Marinus, Leendert ,  WOODHEAD, Steven, John ,  WYATT, Paul, Graham ,  BOYLE, Robert, George ,  SORE, Hannah, Fiona ,  WALKER, David, Winter ,  COLLINS, Ian ,  DOWNHAM, Robert ,  CARR, Robin, Arthur, Ellis

IPC分类号： C07D231/12 ,  C07D413/10 ,  C07D401/10 ,  A61K31/415 ,  A61P37/02

CPC分类号： A61K31/415 ,  A61K9/0019 ,  A61K9/20 ,  A61K9/48 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06 ,  C07D231/12 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D413/10

摘要： The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between Rl and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; Rl is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.

公开(公告)号：EP1706385B1

公开(公告)日：2010-10-06

申请号：EP04806258.2

申请日：2004-12-23

申请人： Astex Therapeutics Limited ,  Cancer Research Technology Limited ,  The Institute of Cancer Research: Royal Cancer Hospital

发明人： BERDINI, Valerio ,  SAXTY, Gordon ,  VERDONK, Marinus, Leendert ,  WOODHEAD, Steven, John ,  WYATT, Paul, Graham ,  BOYLE, Robert, George ,  SORE, Hannah, Fiona ,  WALKER, David, Winter ,  COLLINS, Ian ,  DOWNHAM, Robert ,  CARR, Robin, Arthur, Ellis

IPC分类号： C07D231/12 ,  C07D413/10 ,  C07D401/10 ,  A61K31/415 ,  A61P37/02

CPC分类号： A61K31/415 ,  A61K9/0019 ,  A61K9/20 ,  A61K9/48 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06 ,  C07D231/12 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D413/10

公开(公告)号：EP1904451A1

公开(公告)日：2008-04-02

申请号：EP06755591.2

申请日：2006-06-21

申请人： Astex Therapeutics Limited ,  THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL ,  Cancer Research Campaign Technology Limited ,  AstraZeneca AB

发明人： WOODHEAD, Steven, John ,  DOWNHAM, Robert ,  HAMLETT, Christopher ,  HOWARD, Steven ,  SORE, Hannah, Fiona ,  VERDONK, Marinus, Leendert ,  WALKER, David, Winter ,  LUKE, Richard, William, Arthur

IPC分类号： C07D231/12 ,  A61K31/415 ,  A61P37/02

CPC分类号： C07D231/12

摘要： The invention provides a compound of the formula (II): or a salt, solvate, tautomer or N-oxide thereof; wherein n is 0 or 1; one of Y1 and Y2 is CH and the other is selected from CH, CR8 and N; q is 0, 1 or 2 provided that q is 0 or 1 when Y1 or Y2 is CR8; R1 is an aryl or heteroaryl group of 5 to 10 ring members; R2a and R3a each are hydrogen, C1-4 hydrocarbyl or C1-4 acyl wherein the hydrocarbyl and acyl moieties are optionally substituted by fluorine, hydroxy, amino, methylamino, dimethylamino or methoxy; or NR2aR3a forms an imidazole group or a saturated monocyclic 4-7 membered heterocyclic group optionally containing a second heteroatom ring member selected from O and N; R18 is hydrogen or methyl; R19 is hydrogen or methyl; R24 is hydrogen or R24, R2a and the intervening nitrogen atom and carbon atoms together form an azetidine, pyrrolidine or piperidine ring; R25 is hydrogen or a C1-4 alkyl group wherein the C1-4 alkyl group is optionally substituted by hydroxy or amino provided that there are at least two carbon atoms between the hydroxy or amino group and the oxygen atom to which R25 is attached; and R4 and R5 each are hydrogen or a substituent as defined in the claims

公开(公告)号：EP2029592A1

公开(公告)日：2009-03-04

申请号：EP07732559.5

申请日：2007-04-25

申请人： Astex Therapeutics Limited ,  The Institute of Cancer Research : The Royal Cancer Hospital ,  Cancer Research Technology Limited ,  AstraZeneca AB

发明人： WOODHEAD, Steven, John ,  HAMLETT, Christopher ,  SORE, Hannah, Fiona ,  WALKER, David, Winter ,  VERDONK, Marinus, Leendert ,  COLLINS, Ian ,  CALDWELL, John ,  CHEUNG, Kwai-Ming ,  DA FONSECA MCHARDY, Tatiana, Faria

IPC分类号： C07D471/04 ,  C07D487/04 ,  A61K31/437 ,  A61K31/519 ,  A61P35/00

CPC分类号： C07D487/04 ,  C07D471/04 ,  C07D473/00 ,  C07D473/34

摘要： The invention provides compounds of the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein J1-J2 is CH=CH, N=CH, CH=N, HN-C(O) or CH2CO; T is N or CH and GP is as defined in the claims. The compounds have activity as inhibitors of PKA and PKB kinases and are useful in the treatment of cancers.

公开(公告)号：EP1919875A2

公开(公告)日：2008-05-14

申请号：EP06755590.4

申请日：2006-06-21

申请人： Astex Therapeutics Limited ,  The Institute of Cancer Research : The Royal Cancer Hospital ,  AstraZeneca AB

发明人： SORE, Hannah, Fiona ,  BOYLE, Robert, George ,  HAMLETT, Christopher ,  SAXTY, Gordon ,  VERDONK, Marinus, Leendert ,  WALKER, David, Winter ,  WOODHEAD, Steven, John ,  HOWARD, Steven

IPC分类号： C07D231/12 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14

CPC分类号： C07D231/12 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/14 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14

摘要： The invention provides a compound of the formula (I) or a salt, solvate, tautomer or N-oxide thereof; wherein A is a saturated hydrocarbon linker group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; L1 is a bond or a linker selected from C1-C4 alkenylene, C1-C4 alkynylene, -CONR’, -NR’CO, -S-, -C(O)-, -C(NR11)-, -C(S)-, -N(R11)2, C(=CHR11), -SO- and -SO2-; or L1 together with t R16 forms an 8-12 membered fused bicyclic heteroaryl ring system; L3 is a bond or a linker selected from CONH and HNCO; provided that L1 and L3 cannot both be linkers simultaneously; and provided also that L1 and L3 cannot both be a bond simultaneously; R16 is an optionally substituted 5- to 12-membered monocyclic or bicyclic carbocyclic or heterocyclic ring; L2 is absent or is a linker selected from C]-C4 alkylene, Ci-C4 alkenylene, Ci-C4 alkynylene, -CONR’-, -NR’CO-, -O-, -S-, -C(O)-, C(=CHR11), C(S)-, -N(R11)2, C3-4 cycloalkanediyl, -SO- and -SO2-; R17 is absent or is C1-6 alkyl or an optionally substituted 5 to 12 membered carbocyclic or heterocyclic ring; provided that when R17 is absent, then L2 is also absent; and R2, R3, R4, R5, R11 and R’ are as defined in the claims. Compounds (I) modulate (PKA) and (PKB).